Blog

Thermo Fisher Scientific to Invest $2 Billion in U.S. Manufacturing and R&D Thermo Fisher Scientific, a leading producer of medical instruments and diagnostics, has unveiled plans to invest an additional $2 billion in the United States over the next four years. This sizeable investment comes in the wake of increasing pressure from tariffs under the…

Tariff Hits on Generic Drugs: A Looming Crisis for the U.S. Healthcare System As discussions around the Trump administration’s potential pharmaceutical import tariffs gain traction, a new perspective has emerged highlighting the unique vulnerabilities of the generic drug industry. Ronald Piervincenzi, Ph.D., CEO of the United States Pharmacopeia (USP), argues that generic medicines and their…

AstraZeneca Rejoins Leading U.S. Drug Lobby Group After Two-Year Absence In a strategic move, AstraZeneca (AZN) has rejoined the Pharmaceutical Research and Manufacturers of America (PhRMA), marking its return to this prominent U.S. drug lobby group after a two-year hiatus. The announcement, made on April 23, 2025, underscores AstraZeneca’s commitment to the American market and…

Gilead’s Trodelvy-Keytruda Proposal Advances in First-Line Triple-Negative Breast Cancer Treatment In a significant breakthrough for cancer therapeutics, Gilead Sciences’ Trodelvy has demonstrated its superiority in a first-phase 3 trial, trial dubbed Ascent-04, by effectively prolonging the time before cancer relapse or mortality in patients with previously untreated metastatic triple-negative breast cancer (TNBC). The trial results…

Sanofi and Regeneron Achieve FDA Approval for Dupixent to Treat Chronic Spontaneous Urticaria In a significant development for patients suffering from chronic spontaneous urticaria (CSU), Sanofi and Regeneron have received U.S. Food and Drug Administration (FDA) approval for Dupixent, marking its seventh indication. This milestone comes just 18 months after an initial rejection when the…

Abbott Laboratories Faces Tariff Costs While Achieving Strong Growth in Diabetes Products On April 17, 2025, Abbott Laboratories reported impressive first-quarter earnings that defied a broader market selloff, predominantly driven by robust demand for its diabetes care products. The Chicago-based medical-device company, which operates 90 manufacturing sites globally, disclosed anticipated costs stemming from tariffs that…

Johnson & Johnson Navigates Tariff Challenges with Confidence In a landscape where tariff regulations are constantly evolving, Johnson & Johnson (J&J) is adapting with assurance, even amidst potential trade controversies. The New Jersey-based healthcare giant has recently revised its sales expectations for the year, largely attributing this optimism to a strategic acquisition in the neuroscience…

Americans’ Dangerous Dependence on Foreign-Made Generic Drugs: The Case for Tariffs The issue of America’s dependence on foreign-made pharmaceutical drugs has become a pressing national concern. Over 90% of prescriptions filled in the U.S. are for generic drugs, yet a staggering 80% of the active pharmaceutical ingredients (APIs) necessary for these medications come from overseas,…

Novartis Announces $23 Billion U.S. Investment to Boost Manufacturing and R&D In a significant move to enhance its U.S. operations, Swiss pharmaceutical giant Novartis has unveiled plans to invest $23 billion in building and expanding 10 facilities across the United States over the next five years. This strategic initiative follows similar investment commitments from major…

Novartis Increases U.S. Investment to $23 Billion Amid Industry Trends In a significant move following substantial investment pledges from Eli Lilly and Johnson & Johnson, Switzerland-based Novartis is set to enhance its manufacturing and research capabilities in the United States. The company announced a plan to invest $23 billion over the next five years to…